Cargando…

When and How to Use MIC in Clinical Practice?

Bacterial resistance to antibiotics continues to be a global public health problem. The choice of the most effective antibiotic and the use of an adapted dose in the initial phase of the infection are essential to limit the emergence of resistance. This will depend on (i) the isolated bacteria and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Magréault, Sophie, Jauréguy, Françoise, Carbonnelle, Etienne, Zahar, Jean-Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774413/
https://www.ncbi.nlm.nih.gov/pubmed/36551405
http://dx.doi.org/10.3390/antibiotics11121748
_version_ 1784855401872752640
author Magréault, Sophie
Jauréguy, Françoise
Carbonnelle, Etienne
Zahar, Jean-Ralph
author_facet Magréault, Sophie
Jauréguy, Françoise
Carbonnelle, Etienne
Zahar, Jean-Ralph
author_sort Magréault, Sophie
collection PubMed
description Bacterial resistance to antibiotics continues to be a global public health problem. The choice of the most effective antibiotic and the use of an adapted dose in the initial phase of the infection are essential to limit the emergence of resistance. This will depend on (i) the isolated bacteria and its resistance profile, (ii) the pharmacodynamic (PD) profile of the antibiotic used and its level of toxicity, (iii) the site of infection, and (iv) the pharmacokinetic (PK) profile of the patient. In order to take account of both parameters to optimize the administered treatment, a minimal inhibitory concentration (MIC) determination associated with therapeutic drug monitoring (TDM) and their combined interpretation are required. The objective of this narrative review is thus to suggest microbiological, pharmacological, and/or clinical situations for which this approach could be useful. Regarding the microbiological aspect, such as the detection of antibiotic resistance and its level, the preservation of broad-spectrum β-lactams is particularly discussed. PK-PD profiles are relevant for difficult-to-reach infections and specific populations such as intensive care patients, cystic fibrosis patients, obese, or elderly patients. Finally, MIC and TDM are tools available to clinicians, who should not hesitate to use them to manage their patients.
format Online
Article
Text
id pubmed-9774413
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97744132022-12-23 When and How to Use MIC in Clinical Practice? Magréault, Sophie Jauréguy, Françoise Carbonnelle, Etienne Zahar, Jean-Ralph Antibiotics (Basel) Review Bacterial resistance to antibiotics continues to be a global public health problem. The choice of the most effective antibiotic and the use of an adapted dose in the initial phase of the infection are essential to limit the emergence of resistance. This will depend on (i) the isolated bacteria and its resistance profile, (ii) the pharmacodynamic (PD) profile of the antibiotic used and its level of toxicity, (iii) the site of infection, and (iv) the pharmacokinetic (PK) profile of the patient. In order to take account of both parameters to optimize the administered treatment, a minimal inhibitory concentration (MIC) determination associated with therapeutic drug monitoring (TDM) and their combined interpretation are required. The objective of this narrative review is thus to suggest microbiological, pharmacological, and/or clinical situations for which this approach could be useful. Regarding the microbiological aspect, such as the detection of antibiotic resistance and its level, the preservation of broad-spectrum β-lactams is particularly discussed. PK-PD profiles are relevant for difficult-to-reach infections and specific populations such as intensive care patients, cystic fibrosis patients, obese, or elderly patients. Finally, MIC and TDM are tools available to clinicians, who should not hesitate to use them to manage their patients. MDPI 2022-12-03 /pmc/articles/PMC9774413/ /pubmed/36551405 http://dx.doi.org/10.3390/antibiotics11121748 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Magréault, Sophie
Jauréguy, Françoise
Carbonnelle, Etienne
Zahar, Jean-Ralph
When and How to Use MIC in Clinical Practice?
title When and How to Use MIC in Clinical Practice?
title_full When and How to Use MIC in Clinical Practice?
title_fullStr When and How to Use MIC in Clinical Practice?
title_full_unstemmed When and How to Use MIC in Clinical Practice?
title_short When and How to Use MIC in Clinical Practice?
title_sort when and how to use mic in clinical practice?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774413/
https://www.ncbi.nlm.nih.gov/pubmed/36551405
http://dx.doi.org/10.3390/antibiotics11121748
work_keys_str_mv AT magreaultsophie whenandhowtousemicinclinicalpractice
AT jaureguyfrancoise whenandhowtousemicinclinicalpractice
AT carbonnelleetienne whenandhowtousemicinclinicalpractice
AT zaharjeanralph whenandhowtousemicinclinicalpractice